Rapid Analysis of Infections by Spectrometry of Exhaled Breath
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Sep 27, 2017
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new way to diagnose and understand respiratory infections in patients with certain blood disorders, like leukemia or anemia, who are receiving intensive chemotherapy. Researchers want to see if analyzing the breath of these patients using a special technique called spectrometry can help doctors identify infections faster and more accurately. This could be important for improving treatment and outcomes for these patients.
To participate in this study, patients must be at least 18 years old and have specific blood disorders, such as acute myeloid leukemia (AML) or aplastic anemia, and be undergoing certain treatments. They should not currently have signs of an active respiratory infection. If eligible, participants will provide written consent and may undergo breath analysis during their treatment. This trial is currently recruiting, and it aims to gather important information that could lead to better care for patients facing serious health challenges.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18y at start of study
- * One of the following diagnoses:
- • De novo, refractory or relapsed AML/MDS receiving intensive chemotherapy
- • De novo, refractory or relapsed ALL/T-lymphoblastic lymphoma receiving intensive chemotherapy
- • Aplastic anemia requiring ATG therapy
- • Any patient admitted for either autologous hematopoietic stem cell transplantation. Transplantation may not have been performed at time of enrolment.
- • Any patient admitted with allogeneic hematopoietic stem cell transplantation within the last year, or planned during this admission.
- • Written informed consent obtained from the patient
- Exclusion Criteria:
- • Hematological disease beyond the specified inclusion criteria
- • Signs of active respiratory infection
- • If previously enrolled: incomplete clearance of all signs of respiratory infection (both clinically, microbiologically and radiologically).
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials